As senior vice president of global operations, Sridhar will be responsible for integrating business units and provide operational excellence leadership across the Frontage organization
As senior vice president of global operations, Sridhar will be responsible for integrating business units and provide operational excellence leadership across the Frontage organization
EXTON, Pa., May 10, 2019 (Newswire.com) - Frontage Laboratories Inc. announces the appointment of Sridhar Krishnan as senior vice president, global operations. In his role, he will be responsible for integrating business units and provide operational excellence leadership across the Frontage organization.
“We are very excited to welcome Mr. Sridhar Krishnan on board as senior vice president of global operations,” said Dr. Song Li, founder and CEO of Frontage Laboratories. “Sridhar brings a wealth of experiences in operational improvement and business transformation. The combination of his experience, knowledge, drive and culture makes him an ideal fit for this leadership role and for Frontage’s next stages of growth.”
“I look forward to leading our operations with a focus on sustainability, compliance and execution excellence. Operational excellence combined with scientific and commercial excellence will strengthen our ability to serve our customers’ and patients’ needs with speed and quality,” said Sridhar Krishnan.
Sridhar has over 25 years of experiences in operations and over 20 years of experience in pharmaceutical manufacturing and medical devices industries. He has proven track record of leading large, cross-functional global teams, driving enterprise-wide business transformations, strategies, delivering improvements in operational performance, financial/business results and enhancing enterprise value. Sridhar comes to us from Catalent Pharma
Learn more about this appointment at www.frontagelab.com/about/
About Frontage:
We are a CRO providing integrated, scientifically driven, drug product development services throughout the drug discovery and development process to enable biopharmaceutical